Details

Autor(en) / Beteiligte

• Narisety, Satya D., MD
• Skripak, Justin M., MD
• Steele, Pamela, CPNP
• Hamilton, Robert G., PhD
• Matsui, Elizabeth C., MD
• Burks, A. Wesley, MD
• Wood, Robert A., MD

Titel

Open-label maintenance after milk oral immunotherapy for IgE-mediated cow's milk allergy

Ist Teil von

• Journal of allergy and clinical immunology, 2009-09, Vol.124 (3), p.610-612

Ort / Verlag

United States: Mosby, Inc

Erscheinungsjahr

2009

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• Currently, the standard of care is strict food avoidance, although there have been several recent studies with encouraging results using oral and sublingual immunotherapy for the treatment of food allergy.1-8 One such study evaluated the safety and efficacy of oral immunotherapy for cow's milk allergy in a randomized, double-blind, placebo-controlled trial, and this report summarizes the subsequent open-label phase of this study.8 Participants who successfully completed the double-blind portion of the milk oral immunotherapy (MOIT) study were continued on measured dairy intake at home daily.    Milk threshold (mg) End-point titration SPT (dilution) CM IgE (kUa/L) CM IgG4 (μg/mL) Patient Age (y) Sex Baseline Post-MOIT Follow-up (mo)[low *] Baseline Post-MOIT Follow-up (mo)[low *] Baseline Post-MOIT Follow-up (mo)[low *] Baseline Post-MOIT Follow-up (mo)[low *] Active-treated group 1 6 F 40 8,140[dagger] 16,000 (5)[dagger] 1:100 Negative  9.8 11.4 6.5 (14) 4.8 68.1 601.5 (14) 3 15 M 40 4,140 16,000 (9)[dagger] 1:100 1:5 Negative (15) 31.4 496 58.5 (15) 5 24.2 618.2 (15) 4 6 F 40 4,140 10,000 (12) 1:100 1:100 1:1 (10) 42 27 7.7 (17) 3.9 24.4 61.4 (17) 5 8 F 40 8,140 16,000 (6) 1:5 Negative Negative (12) 0.9 1 0.6 (12) 1.5 5.1 11.3 (12) 6 8 F 40 8,140[dagger] 16,000 (4)[dagger] 1:10 Negative Negative (10) 5.6 2.3 1.1 (10) 7.7 730 908.3 (10) 7 11 M 40 8,140[dagger] 16,000 (3)[dagger] 1:50 1:1 Negative (12) 29.9 36.9 6.1 (12) 2.6 16.1 404.1 (12) 8 6 M 40 6,140 16,000 (4) 1:5 1:1  20.4 24.1 20.3 (4) 3 30.1 143.1 (4) 9 10 M 40 6,140 16,000 (17)[dagger] 1:100 1:1 Negative (14) 30.8 31.1 14.2 (15) 2.3 23.1 69.1 (15) 11 6 M 40 8,140 16,000 (3) 1:50 1:5 Negative (9) 13.5 10.3 10.4 (9) 1.6 4.8 80.6 (9) 12 10 M 40 4,140  1:10 1:5  84.3 66.2 30.9 (5) 4.6 33.7 121.9 (5) 13 7 M 140 8,140  1:50 1:100 1:5 (8) 28.4 26.3 13.4 (8) 0.3 1.7 1.3 (8) 14 9 M 40 8,140[dagger] 16,000 (3)[dagger] 1:100 1:1  8.2 7.5 5.6 (3) 2.4 7.4 13.7 (3) 17 6 M 140 3,140 3,000 (3) 1:100 1:5  34.8 40 43 (3) 5 17.2 66.5 (3) 23 16 M 140 4,140 6,000 (5) 1:10 Negative Negative (14) 57.5 74.4 41.8 (5) 18.9 261 337.9 (5) 25 7 F 1,340 8,140 3,000 (9) 1:1 1:1 1:5 (9) 53.5 26.7  8.3 10.6  Median  40 6,140 10,000 (3) 1:50 1:1 Negative (11) 29.9 26.7 11.9 (9.5) 3.9 23.1 101.3 (9.5) P value (baseline to follow-up) .001   .0091   .0355   .001 P value (post-MOIT to follow-up) .0034   .0688   .0035   .0012 Off-protocol subjects 2 11 F 40 1,340  1:100 1:1  119.6 59.7  22.8 133.5  10 12 F 40 2,540 8,000 (11) 1:50 1:10  314 514  5.3 61.7  15 10 M 40 2,540  1:10 1:10  4.9 6.8 2.1 (13) 1.2 12 68.4 (13) Median  40 2,540  1:50 1:10  119.6 59.7  5.3 61.7  Table I Follow-up data summary CM, Cow's milk; F, female; M, male; SPT, skin prick test.